Scholars Central

OtherPublished 21 Jul 2016

Tadalafil in the treatment of lower urinary tract symptoms and erectile dysfunction

Authors: Andrew Myatt, Ian Eardley

Clinical Practice

Volume 5 · Issue 3 · Pages 355

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

In the aging male, erectile dysfunction (ED) and lower urinary tract symptoms (LUTS) are common conditions that have been shown to be related. As life expectancy increases, treatments that target both ED and LUTS will prove increasingly valuable over the coming years. Phosphodiesterase type 5 (PDE5) inhibitors are used primarily to treat ED. Recently, studies have shown that improvements in LUTS are also seen with PDE5 inhibitor treatment. In particular, the PDE5 inhibitor tadalafil may be beneficial owing to its unique long-acting pharmacokinetic properties. We review the current literature to provide an insight into how tadalafil could provide symptomatic relief from ED and LUTS.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Practice
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Andrew Myatt”
  • BylineArticles whose byline prints “Ian Eardley”